Speculation has abounded of late that Bristol-Myers Squibb Co. is looking to do its largest acquisition ever – to add a crown jewel to its string-of-pearls. That’s the pharma’s nickname for an aggressive deal-making strategy in which it has lined up a series of about two dozen acquisitions and partnerships to complement its internal pipeline and existing products.
These deals largely have been focused on cancer, cardiovascular disease, immunology, neuroscience and virology Also see "With The Launch Of Yervoy, Early Signs Of R&D Success For Bristol" -...
